Navigation Links
Clinical Data Reported on Vidaza in Hematologic Malignancies and,Advanced Solid Tumors

sed on current expectations and involve a number of known and unknown risks and uncertainties that could cause the final results to differ significantly from the results summarized by such statements. Some of the clinical trials described in this release are being conducted by independent investigators and Pharmion does not control and cannot predict the final results of those trials. Top line or preliminary results may not be confirmed upon full analysis of the detailed results of a trial and additional information relating to the safety, efficacy or tolerability of Vidaza may be discovered upon further analysis of clinical trial data and upon review and analysis of data from other clinical trials. Additional risks and uncertainties relating to Pharmion and its business can be found in the "Risk Factors" section of Pharmion's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2007, its Annual Report on Form 10-K for the year ended December 31, 2006 and in Pharmion's other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made, and Pharmion undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise. Pharmion also disclaims any duty to comment upon or correct information that may be contained in reports published by the investment community.

# # #

-------------------

(Back to top)

PHARMION AND METHYLGENE REPORT PRELIMINARY DATA FOR MGCD0103 AT THE 43rd AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING

HDAC INHIBITOR MGCD0103 DEMONSTRATES substantial RESPONSE RATE IN TWO CLINICAL TRIALS

40% Response Rate and 45% Disease Control Rate in Single-Agent Phase II Trial in Refractory or Relapsed Hodgkin's Lymphoma Patients

30% Response Rate (37% at Relevant Active Doses) in Phase I/II Combination Trial with Vidaza(r) in MD
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
Post Your Comments:
(Date:10/1/2014)... , Oct. 1, 2014 NeuroCall, Inc., ... accreditation for its Telestroke and Teleneurology services. Dr. ... NeuroCall, commented, "We are extremely proud that our quality ... as we continue to provide lifesaving support and continuity ... affiliated hospitals throughout the United States ...
(Date:10/1/2014)... , Oct. 1, 2014  Express Scripts (NASDAQ: ... available 2015 Express Scripts Medicare ® Prescription Drug ... featuring Walgreens (NYSE: WAG ) (NASDAQ: ... choice and clinical support  for their Medicare dollars. ... Medicare Value or Choice plans ...
(Date:10/1/2014)... Calif. , Oct. 1, 2014 /PRNewswire/ ... ), a clinical-stage biopharmaceutical company focused on ... positive results from its 371 patient Phase ... with constipation-predominant irritable bowel syndrome (IBS-C).  Results ... clinically meaningful improvement in IBS-C symptoms for ...
Breaking Medicine Technology:NeuroCall Awarded Joint Commission Accreditation 2Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 2Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 3Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 4Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 2Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 3Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 4Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 5Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 6
... , , , RIVIERA BEACH, Fla., Dec. ... for 40 years, announces the launch of the Sigma Elite, ... the Sigma Elite is available on each monoplace chamber model ... , The Sigma Elite New "Smart Hyperbaric System" includes: , ...
... STAMFORD, Conn., Dec. 14 Zargis Medical Corp., a majority-owned ... spin-off from Siemens Corporate Research (NYSE: SI ) ... Cardioscan(TM) system on Amazon.com, America,s largest online retailer. , Cardioscan ... Popular Science magazine,s "2009 Innovation of the ...
Cached Medicine Technology:Perry Baromedical Announces New Cutting Edge Technology With Patient Data Capture Capability 2Zargis Cardioscan 'The Intelligent Stethoscope' Now Available on Amazon.com 2
(Date:10/1/2014)... October 01, 2014 Phoseon Technology, the ... continues to expand the business worldwide. This rapid growth ... additional capacity for manufacturing efforts. The company has experienced ... five years and expects this growth to continue in ... technology gains worldwide adoption. , “We are very ...
(Date:10/1/2014)... Conn. (PRWEB) October 01, 2014 ... company, including a redefined mission and visual identity ... power of partnering with them to create greater ... agile brand that focuses on empowering customers to ... communications. , The crown jewel of the rebrand ...
(Date:10/1/2014)... from Duke Medicine suggests that some people who are ... hard-wired to gain weight when exposed to chronic stress, ... 13 percent of people, all of whom are Caucasian, ... help them reduce heart disease with simple interventions such ... "Genetic susceptibility, psychosocial stress and metabolic factors act in ...
(Date:10/1/2014)... Kennebunkport, Maine (PRWEB) October 01, 2014 ... autoimmune disorders in the U.S., according to figures from ... Autoimmune Related Diseases Association (AARDA), and many of them ... higher chance of having undiagnosed celiac disease. Gluten ... helping raise awareness of undiagnosed celiac disease by publishing ...
(Date:10/1/2014)... 2014 Diet Doc understands that many of ... weight and their dieting attempts could be easily sabotaged by ... hormone diet treatments into their programs as a way ... fast and effective weight loss results, it also allows patients ... to maintain their weight for the future. , Earlier versions ...
Breaking Medicine News(10 mins):Health News:Phoseon Technology Continues to Drive Growth Worldwide 2Health News:Farmington Company Launches Rebrand and New Positioning 2Health News:Gene interacts with stress and leads to heart disease in some people 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 2Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 4
... and District of Columbia get failing grades , , WEDNESDAY, Nov. ... rates, the United States rates a "D," and 18 states ... grades. , That,s the sobering conclusion of the March of ... Wednesday. Not a single state earned an "A." Only one ...
... Bias, Chief Executive Officer of,the National Hemophilia Foundation ... Enterprise magazine in the "On the Move" section ... and women who,have been appointed to new management ... Recent announcements have included leadership posts at,BET, MTV ...
... death (October 18th) Hunter has been,changing the face ... National Spokesperson., CHICAGO, Nov. 12 November ... Foundation (AEOF),joins with Hunter Tylo of CBS,s The ... raise awareness of Epilepsy and educate the public ...
... satisfaction survey shows health improvements, disease ... benefits of plan -, ATLANTA, Nov. 12 One ... 92 percent of members of Care,Improvement Plus feel their health ... satisfaction of the plan,s southeast regional,membership. Of those who feel ...
... vendor of Internet-based diabetes management software MCT-Diabetes, has announced that ... insight and guidance in a regularly scheduled online column to ... ... Acton, MA (PRWEB) November 12, 2008 -- MyCareTeam, Inc., a ...
... Inc. announced today,the launch of MEDVERSATION(TM) ... facilitate more-informed conversations,between U.S. physicians and their ... (infliximab)., This interactive web application, in ... first in its therapeutic class, provides physicians ...
Cached Medicine News:Health News:U.S. Gets a 'D' for Preterm Birth Rates 2Health News:National Hemophilia Foundation's (NHF) CEO Featured in Black Enterprise Magazine 2Health News:November: National Epilepsy Awareness Month Actress Hunter Tylo Turns Tragic Loss Into Hope 2Health News:Georgia and South Carolina Care Improvement Plus Members Overwhelmingly Pleased with Special Needs Plan 2Health News:Nationally Recognized Diabetes Specialist Dr. Steven Edelman to Provide Educational Articles on Diabetes to MyCareTeam's Website Community 2Health News:Nationally Recognized Diabetes Specialist Dr. Steven Edelman to Provide Educational Articles on Diabetes to MyCareTeam's Website Community 3Health News:MEDVERSATION(TM) Website Launched by Centocor to Facilitate Physician-Patient Dialogue About Drug Benefits and Risks 2Health News:MEDVERSATION(TM) Website Launched by Centocor to Facilitate Physician-Patient Dialogue About Drug Benefits and Risks 3Health News:MEDVERSATION(TM) Website Launched by Centocor to Facilitate Physician-Patient Dialogue About Drug Benefits and Risks 4Health News:MEDVERSATION(TM) Website Launched by Centocor to Facilitate Physician-Patient Dialogue About Drug Benefits and Risks 5Health News:MEDVERSATION(TM) Website Launched by Centocor to Facilitate Physician-Patient Dialogue About Drug Benefits and Risks 6
... Sleep Printing Pulse Oximeter ... to address the growing ... that can easily be ... screening for qualifying or ...
Ergonomic design and intuitive operations. Unique DOX digital SpO2 technology improves performance, even under the most challenging clinical conditions....
... The 8600FO is designed ... of MRI users for patient ... Nonin;s Fiber Optic Sensors and ... burns is eliminated, as well ...
The Avant® 9700 combines flexible alarm options, unparalleled non-volatile memory, and Nonins time-honored technology to give you an easy-to-use and efficient monitor....
Medicine Products: